Skip to main content
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. — Investor Relations & Filings

Ticker · VIR ISIN · US92764N1028 US Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2021-02-25 Director's Dealing
Country US United States of America
Listing US VIR

About Vir Biotechnology, Inc.

https://www.vir.bio/

Vir Biotechnology, Inc. is a clinical-stage immunology company that leverages the immune system to treat and prevent serious infectious diseases and other conditions. The company's pipeline is built on two primary technology platforms: a next-generation antibody platform for identifying and optimizing therapeutic candidates, and the PRO-XTEN® protease-releasable masking technology for applications in oncology. Vir's main therapeutic area is infectious diseases, featuring a leading program for chronic hepatitis delta, and is complemented by strategic programs in oncology. The company has demonstrated its capabilities by developing antibody-based medicines for significant health challenges, including COVID-19 and Ebola.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-02-25 English
VIR Q4 2020 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 25, 2021, by Vir Biotechnology, Inc. It announces the issuance of a press release regarding financial results for the quarter ended December 31, 2020. The document states that the press release is attached as Exhibit 99.1 and is incorporated by reference. The text explicitly mentions that the information is being furnished and shall not be deemed "filed" for certain legal purposes, indicating this is an announcement rather than the full financial report itself. The document length is 3633 characters, which is relatively short and consistent with an announcement rather than a full earnings release. The content corresponds to an initial announcement of quarterly financial results, which fits the definition of an Earnings Release (ER). Therefore, the document should be classified as an Earnings Release (ER).
2021-02-25 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or material definitive agreements by a company. The text describes a material definitive agreement between Vir Biotechnology and GSK, including a preliminary collaboration agreement and a stock purchase agreement. It also includes details about the terms, payments, and conditions of these agreements. There is no indication that this is a full annual or quarterly report, audit report, earnings release, or other specific report type. Instead, it is a regulatory filing announcing material events. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it contains detailed information about the agreements, consistent with an 8-K filing.
2021-02-19 English
FORM 4 SUBMISSION
Director's Dealing
2021-02-18 English
FORM 4 SUBMISSION
Director's Dealing
2021-02-18 English
FORM 4 SUBMISSION
Director's Dealing
2021-02-18 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.